Parkinson's Disease Diagnosis
Parkinson's Disease Diagnosis
There is no blood test, no scan and no single finding that establishes Parkinson's disease. The diagnosis is made by a neurologist, on the examination, and it proceeds in three steps: establish that this is parkinsonism at all, look for the features that would point elsewhere, and then find support. The strongest support is not an image but a response — a clear, measurable improvement on an adequate dose of levodopa, recorded rather than remembered. This page sets out what that sequence looks like, what each investigation actually settles, and the warnings that move a person out of this diagnosis and into one of its neighbours.
Three steps: parkinsonism, then exclusion, then support
The first step is to establish parkinsonism, which is a syndrome rather than a disease. It requires bradykinesia plus either a rest tremor or rigidity. Without bradykinesia there is no parkinsonism, whatever the tremor looks like.
The second step is exclusion: a cause that would produce the picture — a dopamine-blocking drug, vascular disease, hydrocephalus, a toxin, a metabolic disorder — and the red flags that point to the atypical syndromes.
The third step is support: a clear and sustained response to dopaminergic treatment, a rest tremor, levodopa-induced dyskinesia, loss of smell, or evidence of cardiac sympathetic denervation. None is decisive alone; the response to medication is the most useful because it also decides whether device treatment is available later.
What the examination actually looks for
The examination is brief and specific. Repeated movements are assessed on both sides — finger tapping, opening and closing the hand, turning the forearm, tapping the foot — and the examiner watches for slowing, decreasing amplitude and interruptions. Because one side begins first, a difference between the hands matters more than the absolute performance of either.
Rigidity is assessed by moving the limb passively, and it is brought out by asking the person to move the opposite limb. Rest tremor is looked for with the hands idle and is characteristically brought out by distraction — counting backwards, or a task with the other hand. An action tremor does the opposite and appears on reaching.
The challenge test, and why "it did not work" needs examining
A dopaminergic challenge carries the most weight. A motor score is recorded, a dose of levodopa or apomorphine is given, and the score is repeated; a meaningful response is conventionally around 30%. The same measurement later establishes candidacy for deep brain stimulation.
When a challenge is negative, the first question is why. The commonest reason for an apparent non-response is not the disease but the dose and its circumstances: too small to be a trial, taken with protein, swallowed when gastric emptying is delayed, or stopped early for nausea that could have been managed. An inadequate trial proves nothing.
One caveat: a good response supports the diagnosis strongly but does not prove it, because some atypical syndromes respond for a while early on. That is why the response is read alongside the red flags, and why the diagnosis is revisited rather than fixed.
Imaging: what each study does and does not settle
MRI at 3.0T excludes rather than confirms: the vascular burden of vascular parkinsonism, the ventricular enlargement of normal-pressure hydrocephalus — one of the few causes treatable directly — structural lesions, and the patterns of the atypical syndromes. In most people with this condition it is unremarkable, and that is the expected result.
DAT SPECT, or DaTscan, images the dopamine transporter. A normal scan in a person with a tremor effectively excludes a degenerative parkinsonism and moves the diagnosis toward essential tremor, drug-induced tremor or a functional tremor — its most valuable use. An abnormal one confirms dopaminergic denervation, which this condition shares with the atypical syndromes.
Blood, urine and genetics: aimed at the treatable
Laboratory testing is aimed at the treatable imitations: thyroid, liver, calcium and electrolytes, and vitamin B12. In anyone diagnosed before 50, Wilson's disease is excluded with copper studies and a slit-lamp examination, because it is treatable and missing it is catastrophic.
Toxic and drug causes come from the history: manganese, carbon monoxide, and — far the commonest — a dopamine-blocking drug. Antipsychotics and anti-nausea drugs such as metoclopramide produce a parkinsonism indistinguishable from this condition, and are often still being taken for a valid reason. Withdrawal is both the test and the treatment.
Genetic testing is considered where onset is early, where several relatives are affected, or where ancestry carries a higher carrier frequency; LRRK2, PRKN, PINK1, SNCA and GBA1 are among those looked for. It is offered with counselling, and it does not change today's treatment.
Red flags: when the diagnosis is somewhere else
The red flags exist because several conditions begin by looking like this one and then diverge. One of them does not overturn a diagnosis, but it changes what is said and what is promised.
| Feature | What it points toward |
|---|---|
| Falls within the first year, or a pull test that is abnormal early | Progressive supranuclear palsy in particular, and the gait-dominant presentation generally. Uncomplicated Parkinson's disease usually preserves postural reflexes for years. |
| Difficulty looking up or down on command | A vertical gaze palsy, which is the signature of progressive supranuclear palsy, and which appears long before the gaze complaint does. |
| Severe autonomic failure early — fainting on standing, urinary incontinence, erectile failure | Multiple system atrophy, in which autonomic failure is a defining feature rather than a late complication. |
| Cerebellar signs, or a pyramidal sign that is not explained | Multiple system atrophy of the cerebellar type, or a structural or vascular cause. |
| Dementia before the motor features, or within a year of them | Dementia with Lewy bodies, in which cognitive fluctuation, visual hallucinations and parkinsonism appear together rather than in sequence. |
| Symmetry at onset, or a predominantly lower-body syndrome with early freezing | Vascular parkinsonism, and normal-pressure hydrocephalus. |
| A rapid course — needing a wheelchair or a bed within five years | Atypical syndromes generally, which progress faster and respond less to medication than this condition does. |
| No response at all to an adequate, properly conducted levodopa trial | Any of the above. It is a reason to reconsider the diagnosis, not a reason to keep escalating the dose. |
| Apraxia, alien limb phenomena, or a markedly asymmetric cortical deficit | Corticobasal syndrome. |
| A dopamine-blocking drug still being taken | Drug-induced parkinsonism, which is reversible, and which is the red flag most often present and most often missed. |
What a complete assessment should return
An assessment worth travelling for answers six things and says which remain uncertain: whether bradykinesia is present and what accompanies it; whether the medication list could be producing it; what imaging excludes; whether the dopaminergic pathway is affected; how large the levodopa response is when measured; and what the non-motor symptoms are doing to the day.
Four things are worth bringing: the complete medication list for the last two years, including anything for nausea, mood, sleep or blood pressure; the imaging images rather than the report; any documented drug challenge; and, if the day fluctuates, a week of notes on doses and hours.
What comes back is a written opinion within about 48 hours of complete records arriving, stating whether the diagnosis is secure, what has been excluded, whether the response to medication has been established or should be measured, and whether anything should be changed before anything new is added. Where the findings do not support the diagnosis, it says that — which is a result, not a failure.